Blog
RSS FeedPosted by Michael Wonder on 14 Dec 2024
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for Pluvicto
13 December 2024 - Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA positive metastatic castration ...
Posted by Michael Wonder on 14 Dec 2024
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Tecentriq SC (atezolizumab solution for subcutaneous injection)
13 December 2024 - Roche Canada today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Tecentriq ...
Posted by Michael Wonder on 01 Dec 2024
BC man calls on federal, provincial governments to cover his costly, life saving cancer treatment
30 November 2024 - Pharmaceutical company Novartis says a five dose treatment costs about $135K. ...
Posted by Michael Wonder on 16 Nov 2024
Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment Pluvicto
15 November 2024 - Novartis Canada is extremely disappointed that negotiations for Pluvicto (lutetium (Lu 177 ) vipivotide tetraxetan injection), ...
Posted by Michael Wonder on 30 Oct 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Verzenio (abemaciclib) in expanded early breast cancer indication
29 October 2024 - Eli Lilly Canada is pleased to announce that it received a positive Canada's Drug Agency (CDA-AMC, formally ...
Posted by Michael Wonder on 29 Oct 2024
Breast Cancer Canada 'Progress Report' reveals major gaps in screening and treatment delays across Canada
28 October 2024 - Breast Cancer Canada has released the 2024 Progress Report on Breast Cancer in Canada. ...
Posted by Michael Wonder on 22 Oct 2024
Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process
21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly. ...
Posted by Michael Wonder on 11 Oct 2024
Roche Canada announces Columvi (glofitamab for injection) is publicly reimbursed in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland
9 October 2024 - Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian ...
Posted by Michael Wonder on 22 Sep 2024
Men get breast cancer, too. But they can't always access new drugs.
21 September 2024 - Breast cancer is widely researched, but some men suffering from the illness say they can’t benefit. ...
Posted by Michael Wonder on 12 Sep 2024
Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Welireg (belzutifan)
5 September 2024 - Merck announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Welireg (belzutifan) on ...
Posted by Michael Wonder on 04 Aug 2024
First time-limited reimbursement recommendation supports earlier patient access to a promising cancer treatment
30 July 2024 - Patients in Canada with advanced-stage lymphoma are one step closer to accessing the first drug to receive ...
Posted by Michael Wonder on 24 Jul 2024
AbbVie's Epkinly receives first ever time-limited reimbursement recommendation by Canada's Drug Agency
23 July 2024 - AbbVie has successfully completed its negotiations with the pan-Canadian Pharmaceutical Alliance and a letter of intent ...
Posted by Michael Wonder on 01 May 2024
'What is the price of comfort?': Oncologist raises concerns about newly approved cancer treatment in Canada
30 April 2024 - A new cancer treatment recently approved in Canada promises to cut treatment time down to just ...
Posted by Michael Wonder on 26 Mar 2024
Cost and value of cancer medicines in a single payer public health system in Ontario, Canada: a cross-sectional study
26 March 2024 - We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, ...
Posted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...